Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the …

…, W Steinbach, BH Tan, AJ Ullmann… - The Lancet infectious …, 2019 - thelancet.com
Mucormycosis is a difficult to diagnose rare disease with high morbidity and mortality.
Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and medical …

[HTML][HTML] Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious …

…, G Maschmeyer, D Teschner, AJ Ullmann… - Annals of …, 2018 - Springer
Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular
those with haematological malignancies undergoing remission-induction chemotherapy for …

[HTML][HTML] Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

…, DJ Winston, J Perfect, AJ Ullmann… - … England Journal of …, 2007 - Mass Medical Soc
Background Patients with neutropenia resulting from chemotherapy for acute myelogenous
leukemia or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal …

[HTML][HTML] A global public health convention for the 21st century

…, K Lee, G Scaglia, C Shahpar, AJ Ullmann… - The Lancet Public …, 2021 - thelancet.com
As shown by COVID-19, infectious diseases with a pandemic potential present a grave
threat to health and wellbeing. Although the International Health Regulations provide a …

[HTML][HTML] Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

AJ Ullmann, JH Lipton, DH Vesole… - … England Journal of …, 2007 - Mass Medical Soc
Background Invasive fungal infections are an important cause of morbidity and mortality
after allogeneic hematopoietic stem-cell transplantation. Methods In an international, …

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non‐neutropenic adult patients

…, PE Verweij, C Viscoli, AJ Ullmann… - Clinical Microbiology …, 2012 - Wiley Online Library
Clin Microbiol Infect 2012; 18 (Suppl. 7): 19–37 Abstract This part of the EFISG guidelines
focuses on non‐neutropenic adult patients. Only a few of the numerous recommendations can …

[HTML][HTML] Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

AJ Ullmann, JM Aguado, S Arikan-Akdagli… - Clinical Microbiology …, 2018 - Elsevier
The European Society for Clinical Microbiology and Infectious Diseases, the European
Confederation of Medical Mycology and the European Respiratory Society Joint Clinical …

[HTML][HTML] Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation

…, RF Duarte, S Haider, AJ Ullmann… - … England Journal of …, 2017 - Mass Medical Soc
Background Cytomegalovirus (CMV) infection remains a common complication after allogeneic
hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the CMV–…

[HTML][HTML] ESCMID guideline for the diagnosis and treatment of biofilm infections 2014

…, D Lebeaux, A Oliver, AJ Ullmann… - Clinical microbiology …, 2015 - Elsevier
Biofilms cause chronic infections in tissues or by developing on the surfaces of medical
devices. Biofilm infections persist despite both antibiotic therapy and the innate and adaptive …

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3 …

…, AH Schmitt-Hoffmann, B Zeiher, AJ Ullmann - The Lancet, 2016 - thelancet.com
Background Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The
SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients …